Tag Archives: Novo

Elli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.  Barron’s Lilly’s Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease  Eli Lilly and Company Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity  CNBC Eli Lilly’s diabetes …

Novo Nordisk continues to slip after outlook cut, obesity drug worries (NVO:NYSE)  Seeking Alpha Wegovy maker Novo’s profit warning triggers $70 billion share rout  Reuters Novo Nordisk, Ozempic Drugmaker, Sees Stock Plunge 20% After Profit Warning  The New York Times NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?  Yahoo Finance Health Care Roundup: Market Talk  The Wall Street Journal Source link

Novo Nordisk stock draws mixed views post guidance cut (NVO)  Seeking Alpha Wegovy maker Novo’s profit warning triggers $70 billion share rout  Reuters NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?  Yahoo Finance Novo Nordisk, Ozempic Drugmaker, Sees Stock Plunge 20% After Profit Warning  The New York Times Novo CEO’s First Test Is Winning Back the US Weight-Loss Market  Bloomberg Source link

Novo Nordisk slides further on US competition, new CEO concerns  Reuters Novo Nordisk Stock Got Battered. Think Twice Before Buying the Dip.  Barron’s Novo CEO’s First Test Is Winning Back the US Weight-Loss Market  Bloomberg.com Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding  NPR European markets close mixed; Novo Nordisk extends losses  CNBC Source link

Novo Nordisk Stock Got Battered. Think Twice Before Buying the Dip.  Barron’s Novo Nordisk slides further on US competition, new CEO concerns  Reuters Novo Nordisk’s stock plunge isn’t surprising. Why companies clear the deck for new CEOs  CNBC Novo Nordisk Shares Plummet as Competition Weighs on Sales  The Wall Street Journal Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug …

Topline Shares of Wegovy and Ozempic maker Novo Nordisk fell more than 21% Tuesday, pacing what would be the stock’s largest plunge since the 1980s after the Danish pharmaceutical firm cut its full-year guidance for sales and profit, as growth for its obesity and weight loss treatments are expected to slow in the U.S. The Danish firm said weaker Wegovy …

Novo Nordisk lowered its sales forecast for obesity drug Wegovy, citing competition from compounded versions. Scott Olson/Getty Images hide caption toggle caption Scott Olson/Getty Images Novo Nordisk’s shares plunged more than 20% Tuesday, after the company cut the forecast for its flagship obesity drug. Before the markets opened, the company announced that sales of its obesity medicine, Wegovy, are expected …

Novo Nordisk, Ozempic Drugmaker, Sees Stock Plunge 20% After Profit Warning  The New York Times Novo Nordisk Shares Plummet as Competition Weighs on Sales  The Wall Street Journal Novo Nordisk shares plunge 23% after Wegovy maker names new CEO, cuts full-year guidance  CNBC Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding  NPR Wegovy maker Novo’s profit warning triggers $70 billion share rout  Reuters Source …

Novo Nordisk Shares Plummet as Competition Weighs on Sales  The Wall Street Journal Novo Nordisk, Ozempic Drugmaker, Sees Stock Plunge 20% After Profit Warning  The New York Times Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook  Yahoo Finance Novo Nordisk shares plunge 23% after Wegovy maker names new CEO, cuts full-year guidance  CNBC Novo Stock (NVO) Tumbles. Ozempic, Wegovy Maker …

SoFi, UnitedHealth, Novo Nordisk, UPS, Boeing, Sarepta, Whirlpool, and More Movers  Barron’s Stocks making the biggest moves premarket: Novo Nordisk, Whirlpool, Sarepta Therapeutics and more  CNBC Procter & Gamble, Sarepta Therapeutics, Cadence Design Systems  TradingView Source link